Abstract
BackgroundRosacea is a common inflammatory skin condition affecting approximately 5% of the world population. Therapeutic approaches to rosacea are focused on symptom suppression by means of anti-inflammatory agents. More recently, photodynamic therapy, especially light-emitting diodes, has been introduced as a valid alternative to conventional therapy.Case presentationIn the present work, we reported the efficacy and safety of light-emitting diodes therapy combining blue (480 nm) and red (650 nm) light for the treatment of two patients with papulopustular rosacea: a 22-year-old Caucasian woman and a 68-year-old Caucasian man.ConclusionsThis kind of treatment could represent an effective, safer, and well-tolerated approach for the treatment of such conditions.
Highlights
Rosacea is a common inflammatory skin condition affecting approximately 5% of the world population
Several therapeutic approaches are currently available for treating rosacea and they are mainly aimed at controlling disease symptoms [40, 41]
The therapeutic plan has to be adapted to the rosacea subtype and tailored
Summary
Rosacea is a common inflammatory skin condition affecting approximately 5% of the world population. Case presentation: In the present work, we reported the efficacy and safety of light-emitting diodes therapy combining blue (480 nm) and red (650 nm) light for the treatment of two patients with papulopustular rosacea: a 22-year-old Caucasian woman and a 68-year-old Caucasian man. Usually referred to as rosacea, is a common inflammatory skin condition affecting mainly the central face [1]. Four subtypes of rosacea can be recognized on the basis of different morphological characteristics: erythematotelangiectatic, papulopustular, phymatous, and ocular [5, 6]. The erythematotelangiectatic subtype is the most common one followed by papulopustular, phymatous and ocular types which are reported as less common [7]. Data from clinical practice show that patients often can harbor more than one
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
